Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate
Synairgen plc has completed its oversubscribed equity fundraising to raise US$114 million to fund a Phase III trial for 900 patients for the effects of its SNG001 drug on patients with COVID-19. In addition the raise will be used to scale up manufacturing and device activities.
Synairgen engages in the provision of respiratory drug discovery and development. It focuses on severe asthma, chronic obstructive pulmonary disease and severe viral infections, as well as COVID-19. The company was founded by Donna E. Davies, Ratko Djukanovic, and Stephen T. Holgate in June 2003 and is headquartered in Southampton.
Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as advisor to Synairgen plc in this transaction.
CEO, Synairgen plc
Talk to the deal team
PartnerLondon, United Kingdom
Spring has completed an equity raise
The owners and management of Spring have completed a fundraising to support its growth strategy.Learn more
CML Group (ASX:CGR) has completed a placement
CML Group (ASX:CGR) has completed a US$2.5 million placement. The raise was completed at an issue price of US$0.238 (A$0.328) per share to institutional and professional investors. Funds raised will be used to support the company’s cash position to fund growth in its loan book.Learn more
GBM Resources (ASX:GBZ) has successfully raised US$4.6 million
GBM Resources Ltd. (ASX:GBZ) has completed a fundraising to accelerate development.Learn more